Yokohama, 8 - 10 October 2025

BioJapan – Yokohama

Meet InnoCore Pharmaceuticals at BioJapan 2025 – Connect with our expert to advance your API into a Long-Acting Injectable

InnoCore Pharmaceuticals will be attinding the BioJapan in Yokohama, where you can meet Chief Business Officer, Martin Bakker.

Martin is eager to discuss our latest developments in Long-Acting injectables and show how we enable sustained delivery of your API without having the typical limitations of aggregation, acylation or a high local pH.

Innovative long-acting injectables

We specialise in developing bespoke biodegradable long-acting injectables which address the irregular and non-intact formulation challenges of PLGA for peptide and biologic therapeutics.

Whether you are developing a second or next-generation formulation with less frequent dosing or are seeking to shift from IV to subQ injections, our SynBiosys® platform offers flexible, proven solutions tailored to your molecule and clinical needs.

Why partner with InnoCore Pharmaceuticals?

• Extensive expertise in sustained-release formulations

• Proven track record in developing bespoke long-acting injectable formulations for peptides, proteins, and other biologics

• Tunable SynBiosys® polymer platform to develop formulations with 1 week or several months sustained release systems; dependable on your needs

• Strong collaborative approach from early-stage development through to clinical supply

Arrange a meeting during the BioJapan!

We would love to discuss how our drug delivery technologies can support your development goals. You can connect with Martin through the BioJapan partnering platform, reach out to us directly the contact form below, or contact us on: +31 50 575 3100

"*" indicates required fields